HeartSciences Inc. (HSCS): Nasdaq/NYSE listing notice — Heart Test Labs gets Nasdaq extension until June 19, 2023 to regain equity compliance

HeartSciences Inc.

Stockholders' equity was $1,082,676 as of Oct 31, 2022, below Nasdaq's $2.5M minimum for continued listing.
Nasdaq granted extension to June 19, 2023 after company submitted a compliance plan.
Company must file a public report describing the transaction/event that restores compliance.
If not compliant by April 30, 2023 filing, Nasdaq may delist; company can appeal to a Hearings Panel.
Warrants (HSCSW) also listed on Nasdaq and subject to same continued listing requirement.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

HeartSciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

February 8, 2023, the Company received a letter from Nasdaq in which it stated, that based on the Company's submission of its plan of compliance to Nasdaq, Nasdaq has determined to grant the Company an extension of time to regain compliance with Nasdaq Listing Rule 5550(b)(1) until June 19, 2023. The Company must furnish to the SEC and Nasdaq a publicly available report (e.g. a Form 8-K) which report, among other things, includes a description of the completed transaction or event that enabled the Company to satisfy the stockholders' equity requirement for continued listing. After filing the p

View on SEC.gov

Browse all listing & compliance notices →

HeartSciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-002646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.